Eli Lilly is investing $27 billion in U.S. manufacturing to expand drug production and secure future supply. The company will ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other high growth mega cap stocks. Exactly 5 years ago, the world struggled to deal with a ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other high growth mega cap stocks. Exactly 5 years ago, the world struggled to deal with a ...

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches ...

Lilly is acquiring all commercial and intellectual property rights to Organovo's FXR program for worldwide development. Organovo is a clinical stage biotechnology company that is developing drugs that ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other top stocks to buy according to sustainable insight capital management. Sustainable Insight ...

So, it's important to know a company's potential revenue growth. For Lilly, the consensus sales estimate for the current quarter of $12.69 billion indicates a year-over-year change of +44.7%.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other non-tech stocks. Investing in non-technology stocks offers a range of benefits that ...

One of two restaurants being investigated on four reports of potential drink tampering is denying the incident has anything to do with them.

Dan Skovronsky knows what makes a good obesity drug. As chief scientific officer at Eli Lilly, he's already done it once with the company's weekly shot, Zepbound. He's trying to do it again with a ...